While luxury fashion is still associated with exclusivity, prestige, and five-figure price tags, the global sector is entering a period of structural transformation as consumer demand weakens and economic uncertainty reshapes spending behavior. Major luxury Read more…
Moving to a state with no income tax on retirement withdrawals sounds like a guaranteed financial win, and the lifestyle change feels well deserved. But hidden expenses can turn a dream move into a financial Read more…
Workday (WDAY) shareholders have had a brutal year, and Wall Street keeps adding to the pile. The enterprise software giant has lost more than half its market value since early 2024, and the downgrades have Read more…
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Why we love this deal Giving your space an overhaul is Read more…
Elon Musk does not often sound like a fiscal policy analyst. But in a Fox News interview that has been recirculating widely as the US approaches another deficit milestone, he made a comparison that is Read more…
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Good cookware is one of the smartest investments you can make. Read more…
This year was supposed to mark a turnaround for the U.S. housing market. After years of high mortgage rates, ever-rising home prices, and millions of homeowners staying put due to their pandemic-era low interest rates, Read more…
When a stock jumps 13% in the session after earnings day, and the analyst covering it still cuts the price target, something interesting is happening, and you may want to dig beneath the surface. That Read more…
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Power outages are a part of life, and although we’ve all Read more…
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near Read more…